India's Semaglutide Market Set for Generic Boom as Patents Expire, Over 50 Brands Lined Up for Launch, See Full List
New Delhi: The expiry of semaglutide's key patent in India in March 2026 is ushering in a tsunami of generic versions of the blockbuster diabetes and weight-loss molecule, leading to what industry insiders are calling a "slum of brands." With the active ingredient behind Wegovy, Ozempic, and Rybelsus facing open competition, more than two dozen Indian pharmaceutical firms are preparing to launch semaglutide-based generics under a bewildering array of names.
A Major GLP-1 Franchise Goes Off Patent
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed by Novo Nordisk under brand names Ozempic (for type-2 diabetes), Wegovy (for chronic weight management), and Rybelsus (the oral formulation for type-2 diabetes), has dominated the obesity and type-2 diabetes market due to its strong clinical results and high patient demand. In India, patents covering semaglutide’s composition and delivery expired or will expire by March 2026, allowing local drugmakers to enter the highly lucrative “anti-obesity/diabetes” space with their own versions.
Also Read: Dr Reddy's Prepares Generic Semaglutide Entry Under Brand Obeda, Targets 60% Price Cut: Report
As per a recent Business Standard report, the recent DCGI clearances for generic semaglutide, including approvals for Sun Pharma’s Noveltreat and Sematrinity, signal the first wave of formal regulatory entries ahead of broader launches.
Prices for the innovators such as Wegovy and Ozempic are high — often above ₹15,000–₹25,000 per month — prompting both price reductions by original manufacturers and intense market interest from generic players.
Also Read: 7 Pharma Firms Eye Generic Semaglutide, Prices May Fall 50% Post Patent Expiry: Report
Why So Many Brands? A Primer on the ‘Slum of Generics’
There are several reasons for the proliferation of branded generics:
1. Patent Expiry Unlocks Competition:
With semaglutide’s exclusivity eroded, any firm with manufacturing and regulatory capability can produce analogues — leading to a free-for-all in brand naming and product positioning.
2. India’s Generics Ecosystem:
India is the “pharmacy of the world,” known for low-cost manufacturing and rapid scale-up of generic APIs and formulations. Multiple players are ready to tap into semaglutide demand for both domestic and export markets.
3. Massive Market Potential:
NDTV reports that Bloomberg analysts estimate the combined obesity and diabetes therapy market could be worth tens of billions globally by the decade’s end; in India alone, semaglutide-class drugs have quickly scaled to hundreds of crores in annual sales.
4. Price Sensitivity and Market Share:
Indian patients are highly price-sensitive, and branded generics with aggressive pricing can rapidly supplant premium innovator therapies, making the segment highly competitive.
Major Semaglutide Generic Brands (India Market Post-Patent)
Brand Name Manufacturer/Marketer
1. Wegovy NovoNordisk
2. Ozempic NovoNordisk
3. Ryblsus NovoNordisk
4. Poviztra emcure
5. Obeda Reddys
6. Mashema Zydus Healthcare
7. Wyntide Corona
8. Semaglip Lloyd
9. Semaglide Alkem
10. Semanat Natco Pharma
11. Semanta Ajanta Pharma
12. Samakind Mankind Pharma
13. Semastar Torrent Pharmaceuticals
14. Semaglut Anthem Biopharma
15. Semaglyn Zydus Healthcare
16. Sematop Ajanta Pharma
17. Semalite Macleods Pharmaceuticals
18. Semaday Macleods Pharma
19. Semathem Themis Medicare Ltd
20. Semapride Micro Labs
21. Semastrike Unison Pharma
22. Semazit Glenmark Pharma
23. Semalup Lupin
24. Zepsema Torrent Pharmaceuticals
25. Semabig Msn Laboratories
26. Semavance Aristo Pharma
27. Trusema Torrent Pharmaceuticals
28. Semaglura Akums Drugs Pharma
29. Semaglu Vida Laboratories Ltd.
30. Semalembic Alembic Pharma
31. Semadirect Aristo Pharma
32. Semaro Alembic Pharma
33. Glusema Cue Labs Pharma
34. Semavic Alkem Laboratories
35. Semaliv Amon Biotech
36. Sematide Blisson Medica
37. Semafit Ajanta Pharma
38. Noveltreat Sun Pharma
39. Sematrinity Sun Pharma
40. Semaryl Intas Pharmaceuticals
41. Zyglutide Hab Pharmaceuticals
42. Semgluta Mankind Pharma
43. Semaglu Mankind Pharma
44. Semglee Mylan Pharmaceuticals
45. Seglu Torrent Pharmaceuticals
46. Semagla Linux Laboratories
47. Semglyn Zydus Healthcare
48. Semglide Medicamen Life Sc.
49. Semaclu Heet Healthcare
50. Diagluton Dr. Reddys Laboratories
51. Obesema Alkem Laboratories
52. Glp S Alkem Laboratories
53. Glp 1 Neo Ethecom Biosciences
54. Mesemra Alkem Laboratories
55. Semalix Torrent Pharmaceuticals
What Comes Next: Price Wars and Access Expansion
Once generics launch, price erosion is expected to be steep — possibly up to 50–80% below current branded costs — making semaglutide therapies far more affordable for both obesity and diabetes patients.
Industry watchers anticipate that market dynamics will shift from premium mono-brand dominance to fragmented “branded generics wars,” where multiple manufacturers seek share through pricing, pen delivery innovations, and distribution networks, thereby democratizing access, reports TOI.
While cheaper generics could dramatically expand patient access, clinicians warn about appropriate use and medical supervision, especially given widespread interest (and some off-label demand) for obesity indications. Regulatory oversight and physician guidance remain critical.
